← Human Trials & Peer-Reviewed Studies
Growth hormone pulsatility profile characteristics following acute heavy resistance exercise.
Plain-language guide to PMID 11408427 (2001): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 11408427
- Journal
- Journal of applied physiology (Bethesda, Md. : 1985)
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Nindl BC et al. (4 authors)
- DOI
- 10.1152/jappl.2001.91.1.163
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
The Pulsar peak detection system was used to evaluate the pulsatility profile characteristics of hGH.
Why It Was Studied
The AHRE was conducted from 1500 to 1700 and was a high-volume, multiset exercise bout.
Three different immunoassays measured hGH concentrations: the Nichols immunoradiometric assay (Nichols IRMA), National Institute of Diabetes and Digestive and Kidney Diseases radioimmunoassay (NIDDK RIA), and the Diagnostic Systems Laboratory immunofunctional assay (DSL IFA).
Who Took Part
The age groups tagged for this paper are adults, men only.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
What Was Measured
Three different immunoassays measured hGH concentrations: the Nichols immunoradiometric assay (Nichols IRMA), National Institute of Diabetes and Digestive and Kidney Diseases radioimmunoassay (NIDDK RIA), and the Diagnostic Systems Laboratory immunofunctional assay (DSL IFA).
PubMed files the paper under topics including Human Growth Hormone, Immunoassay, Immunoradiometric Assay, Osmolar Concentration, Pulsatile Flow, Radioimmunoassay and Weight Lifting.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The publication is from 2001 (Journal of applied physiology (Bethesda, Md. : 1985)), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.